Prilosec has efficacy, but not indication for NSAID-induced ulcers

Article Abstract:

Astra-Merck's Prilosec (omeprazole) is found to be more effective in preventing and treating ulcers, and for maintenance therapy in patients with ulcers linked with nonsteroidal anti-inflammatory drug (NSAID) use. The discovery is based on two separate multi-nation studies by ASTRONAUT and OMNIUM. However, an Astra-Merck spokesperson said the company prefers not to give a statement regarding the studies since the drug is not meant for NSAID-associated ulcers, but for short-term treatment of active duodenal and gastric ulcers, erosive esophagitis and gastroesophageal reflux disease. The studies indicate that Prilosec is better than Glaxo Wellcome's Zantac in the prevention and treatment of ulcers, and better than Searle's Cytotec for maintenance therapy of NSAID-associated ulcers.

Product information, Antiulcer Preps ex Antacids, Antiulcer agents, Astra-Merck, Prilosec

---

DuPont buys out Merck's interest in joint venture

Article Abstract:

DuPont has acquired Merck & Co.'s 50% stake in their joint-venture company, DuPont Merck Pharmaceutical Co. Merck was paid $2.6 billion by DuPont for its 50% ownership of DuPont Merck Pharmaceutical, with the deal placing DuPont Merck's value at $5.2 billion. Merck decided to sell its half ownership of DuPont Merck because the company does not expect the joint venture to be a significant contributor to the overall growth of Merck. DuPont, on the other hand, opted to buy out Merck from their joint venture because it sees DuPont Merck as an important part of its efforts to concentrate on life sciences in achieving growth.

Asset sales & divestitures, Acquisitions & mergers, Pharmaceutical Preparations, Drugs, E.I. du Pont de Nemours and Co., Merck & Company Inc., DuPont Merck Pharmaceutical Co.

---

Pravachol top DTC brand, Glaxo largest advertiser

Article Abstract:

Bristol-Myers Squibb invested the highest DTC expenditure of $22.7 million into its Pravachol medication for the first quarter of 1998. The Competitive Media Reporting and Publishers Information Bureau indicated that 50% of that amount was spent for the balance in newspapers and magazines, as well as network television. Glaxo Wellcome allotted $41.1 million for its DTC advertising budget, which bested that of Merck at $28.3 million as well as Bristol-Myers. The amount was the highest yet. The ten leading firms contributed $189.9 million in expenditures for 90% of the total during the first quarter of 1998.

United Kingdom, Marketing procedures, Hormones & Related Preparations, Glaxo Wellcome PLC, Bristol-Myers Co., Pravachol

Similar abstracts:

• Abstracts: Patients, physicians, and professional knowledge: implications for CQI. Physician practice acquisitions: valuation issues and concerns
• Abstracts: Peer-identified expert nurses' approaches to risk assessment for pressure ulcers. Intraoperatively acquired pressure ulcer prevalence: a national study
• Abstracts: Clinical benchmarking: implications for perinatal nursing. Developing a service line approach to quality improvement
• Abstracts: Does increasing the beer tax reduce marijuana consumption? Modeling risk using generalized linear models. Statistical inference of progressivity dominance: an application to health care financing distributions
• Abstracts: How to leverage a bad inventory situation. How to get parts out of prison (without paperwork). Doing more with less: smart stockroom management equals great service

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.